Can Amphastar Pharmaceuticals (AMPH) Navigate Heightened Trade Tensions to Protect Its Supply Chain Advantage?

• In the past week, concerns about escalating trade tensions between the US and China, triggered by comments from President Donald Trump, prompted a broad sell-off among healthcare and technology stocks, including Amphastar Pharmaceuticals. This market-wide reaction was driven by apprehension over potential supply chain disruptions and increased costs for companies reliant on international trade.
• Interestingly, despite the White House choosing not to impose tariffs on imported generic drugs, sector sentiment remains sensitive to global trade developments, emphasizing the interconnectedness of pharmaceutical supply chains.
• We’ll examine how renewed trade concerns and sector-wide volatility may influence Amphastar Pharmaceuticals’ investment outlook and industry positioning.

Rare earth metals are the new gold rush. Find out which 35 stocks are leading the charge.

Amphastar Pharmaceuticals Investment Narrative Recap

To be a shareholder in Amphastar Pharmaceuticals, you have to see value in its growing U.S. manufacturing capacity and ability to diversify revenue through new product launches, while facing ongoing pressure from generics pricing and competition. The recent trade tensions may unsettle sector sentiment, but with no new tariffs on generic drugs and Amphastar’s domestic ramp-up, near-term operational risk from this event appears limited; the biggest short-term challenge remains pricing and margin compression in core products.

A recent exclusive license agreement with Nanjing Anji Biotechnology Co. Ltd. stands out, bringing three new peptides into Amphastar’s U.S. and Canadian portfolios. While this development broadens the potential product pipeline and could help offset revenue declines in established generics, its contribution to immediate growth is likely to be incremental rather than transformative, especially with sector-wide volatility in play.

Still, in contrast to the relative stability offered by tariff relief, investors should be aware of how margin declines and competitive pressure in major injectable products could…

Read the full narrative on Amphastar Pharmaceuticals (it’s free!)

Amphastar Pharmaceuticals is expected to reach $830.2 million in revenue and $142.5 million in earnings by 2028. This outlook is based on a forecast annual revenue growth rate of 4.7% and reflects a $7.8 million increase in earnings from the current $134.7 million figure.

Uncover how Amphastar Pharmaceuticals’ forecasts yield a $32.00 fair value, a 35% upside to its current price.

Exploring Other Perspectives

Simply Wall St Community members contributed four separate fair value estimates for Amphastar Pharmaceuticals, spanning a wide US$32 to US$84.72. With uncertainty in pricing power and sector competition, the diversity of these views highlights why broad perspectives matter for assessing Amphastar’s performance.

Explore 4 other fair value estimates on Amphastar Pharmaceuticals – why the stock might be worth over 3x more than the current price!

Build Your Own Amphastar Pharmaceuticals Narrative

Disagree with existing narratives? Create your own in under 3 minutes – extraordinary investment returns rarely come from following the herd.

Want Some Alternatives?

Don’t miss your shot at the next 10-bagger. Our latest stock picks just dropped:

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com